These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23399586)

  • 1. The role of serotonin in the antidyskinetic effects of deep brain stimulation: focus on antipsychotic-induced motor symptoms.
    Creed MC; Nobrega JN
    Rev Neurosci; 2013; 24(2):153-66. PubMed ID: 23399586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei.
    Creed MC; Hamani C; Bridgman A; Fletcher PJ; Nobrega JN
    J Neurosci; 2012 Jul; 32(28):9574-81. PubMed ID: 22787043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early gene mapping after deep brain stimulation in a rat model of tardive dyskinesia: comparison with transient local inactivation.
    Creed MC; Hamani C; Nobrega JN
    Eur Neuropsychopharmacol; 2012 Jul; 22(7):506-17. PubMed ID: 22153973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep brain stimulation of the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
    Creed M; Hamani C; Nobrega JN
    Eur Neuropsychopharmacol; 2011 May; 21(5):393-400. PubMed ID: 20624675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of serotonin receptors in the action of atypical antipsychotic drugs.
    Meltzer HY; Massey BW
    Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Severe treatment-resistant tardive dystonia: is deep brain stimulation a treatment option].
    Mentzel CL; Tenback DE; Tijssen MA; van Harten PN
    Tijdschr Psychiatr; 2015; 57(2):125-31. PubMed ID: 25669951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonergic mechanisms as targets for existing and novel antipsychotics.
    Meltzer HY
    Handb Exp Pharmacol; 2012; (212):87-124. PubMed ID: 23129329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tardive dyskinesia: clinical presentation and treatment.
    van Harten PN; Tenback DE
    Int Rev Neurobiol; 2011; 98():187-210. PubMed ID: 21907088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors.
    Ohno Y; Imaki J; Mae Y; Takahashi T; Tatara A
    Neuropharmacology; 2011; 60(2-3):201-8. PubMed ID: 20813116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery for tardive dyskinesia.
    Thobois S; Poisson A; Damier P
    Int Rev Neurobiol; 2011; 98():289-96. PubMed ID: 21907092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic involvement in haloperidol-induced catalepsy.
    Neal-Beliveau BS; Joyce JN; Lucki I
    J Pharmacol Exp Ther; 1993 Apr; 265(1):207-17. PubMed ID: 8386235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
    Haleem DJ; Samad N; Haleem MA
    Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
    Basile VS; Ozdemir V; Masellis M; Meltzer HY; Lieberman JA; Potkin SG; Macciardi FM; Petronis A; Kennedy JL
    Mol Psychiatry; 2001 Mar; 6(2):230-4. PubMed ID: 11317228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
    Bishnoi M; Kumar A; Chopra K; Kulkarni SK
    Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs.
    Tarsy D; Lungu C; Baldessarini RJ
    Handb Clin Neurol; 2011; 100():601-16. PubMed ID: 21496610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.